Floatz logo

Cabergoline

Acromegaly

RECORDATI GROUPSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Acromegaly cohort.

Asset / SponsorPhaseRating
Pasireotide
RECORDATI GROUP
Phase 4B

Same molecule, other indications

Cabergoline is also rated in:

Cushing disease due to pituitary adenomaDormant
BB
Indicative ·
69 / 100
View asset →
pituitary tumorDormant
BB
Indicative ·
69 / 100
View asset →
ectopic ACTH secretion syndromeDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →